Daniel E Freeman

US Patent:

20200140954, May 7, 2020

Filed:

Aug 21, 2019

Appl. No.:

16/547434

Inventors:

- Tokyo, JP
- Martinsried, DE
- Thousand Oaks CA, US
Daniel J. FREEMAN - Holmdel NJ, US
Robert Allen BECKMAN - Blue Bell PA, US
Xiaoping JIN - Hillsborough NJ, US

Assignee:

Daiichi Sankyo Co., Ltd. - Tokyo
U3 Pharma GmbH - Martinsried
AMGEN, INC. - Thousand Oaks CA

International Classification:

C12Q 1/6886
C07K 16/32
C07K 16/28
A61K 39/395
A61K 45/06

Abstract:

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.

US Patent:

20170308608, Oct 26, 2017

Filed:

May 1, 2017

Appl. No.:

15/583857

Inventors:

Daniel Freeman - Tampa FL, US

International Classification:

G06F 17/30
H04W 4/20
G06Q 50/00

Abstract:

A method for comprehensive user/event matching or recommendations is described. The method includes a network environment which receives one or more pieces of user data, event data, or social data from users or third party data sources, determining the relevance of the data for users, and displaying the identified data to user in the form of recommendations.

US Patent:

20170166973, Jun 15, 2017

Filed:

Oct 19, 2016

Appl. No.:

15/297775

Inventors:

- Tokyo, JP
- Martinsried,, DE
- Thousand Oaks CA, US
Daniel J. FREEMAN - Holmdel NJ, US
Robert Allen BECKMAN - Blue Bell PA, US
Xiaoping JIN - Hillsborough NJ, US

Assignee:

Daiichi Sankyo Co., Ltd. - Tokyo,
U3 Pharma GmbH - Martinsried,
AMGEN, Inc. - Thousand Oaks CA

International Classification:

C12Q 1/68
A61K 39/395
A61K 45/06
C07K 16/32

Abstract:

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.

US Patent:

20150152508, Jun 4, 2015

Filed:

Sep 30, 2014

Appl. No.:

14/502792

Inventors:

- Tokyo, JP
- Martinsried, DE
Daniel J. FREEMAN - Holmdel NJ, US
Robert Allen BECKMAN - Blue Bell PA, US
Xiaoping JIN - Hillsborough NJ, US

Assignee:

Daiichi Sankyo Company, Limited - Tokyo
U3 Pharma GmbH - Martinsried

International Classification:

C12Q 1/68
C07K 16/28

Abstract:

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.

US Patent:

20150147326, May 28, 2015

Filed:

Sep 30, 2014

Appl. No.:

14/502769

Inventors:

- Tokyo, JP
- Martinsried, DE
- Osaka, JP
Daniel J. FREEMAN - Holmdel NJ, US
Robert Allen BECKMAN - Blue Bell PA, US
Xiaoping JIN - Hillsborough NJ, US
Kimio YONESAKA - Osakasayama City, JP
Kazuhiko NAKAGAWA - Osakasayama City, JP

Assignee:

Daiichi Sankyo Company, Limited - Tokyo
U3 Pharma GmbH - Martinsried
Kinki University - Osaka

International Classification:

G01N 33/574
C07K 16/40
A61N 5/10
A61K 31/517
A61K 45/06
C07K 16/28
A61K 39/395

US Classification:

4241361, 4241581, 4241421, 4241331, 435 29, 436501, 435 71, 435 792, 435 794, 435 772, 600 1

Abstract:

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step.

US Patent:

20140365484, Dec 11, 2014

Filed:

Mar 14, 2014

Appl. No.:

14/211867

Inventors:

Daniel Freeman - Tampa FL, US

International Classification:

H04L 12/26
G06F 17/30

US Classification:

707736

Abstract:

A method for comprehensive user/event matching or recommendations is described. The method includes a network environment which receives one or more pieces of user data, event data, or social data from users or third party data sources, determining the relevance of the data for users, and displaying the identified data to user in the form of recommendations.